Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs discussed earlier. Cancer drug Verzenio, type 2 diabetes drug Jardiance, and autoimmune disease drug Taltz are all blockbusters with strong sales momentum.

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

Blockbuster weight loss drugs have been arguably the biggest health story of the last several years — and there are no signs their popularity will slow down anytime soon. Millions of Americans have taken the drugs,

The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has allowed cheaper, off-brand versions to flourish.

Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the revenue potential of these drugs.

Weight loss drugs are all the rage right now. From the more popular options like Mounjaro or Ozempic – which is technically a diabetes medication that also helps with weight management – to emerging medications like WeGovy and Zepbound,

Patients will have to draw the medication from a syringe, similar to what people who take compounded weight management drugs have to do. The vials are a cheaper alternative for people who don’t have health insurance,